AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
ENTRESTO has 7.7 points less BS than the average for Medical Devices, Pharma & Biotech.
Medical Devices, Pharma & Biotech BS: ENTRESTO (entresto.com)
This is a highly regulated pharmaceutical site that is technically sloppy but substantively honest. It scores low on the BS meter because pharmaceutical compliance forces a level of transparency (side effects, contraindications) that marketing-led industries avoid, even though its technical implementation (H1 tags and Schema) is a failure.
Fix the heading hierarchy immediately by replacing the ‘Interest-Based Ads’ H1 with content-relevant titles like ‘About ENTRESTO (sacubitril/valsartan)’. Implement Organization and Drug schema to provide a verifiable digital footprint for the brand and its manufacturer. Add direct, outbound citations to published clinical trial results in the New England Journal of Medicine or similar peer-reviewed journals to substantiate efficacy claims. Replace generic imagery placeholders (‘Not actual patients’) with links to real-world evidence data sets or patient registry summaries.
The site maintains high information density regarding safety and symptoms, though it relies on some brand-heavy power words like ‘ENTRUST YOUR HEART’ and ‘world of possibilities’. Substance is found in the specific naming of active ingredients (sacubitril, valsartan) and the granular breakdown of heart failure symptoms (e.g., 3+ pounds weight gain in a day). However, there is significant concept repetition across pages regarding heart failure changing heart structure, which pads the word count without adding new clinical data.
AI treats every internal link as a semantic statement — not a navigation hint. Validate your entity level link signals and confirm whether your anchors reinforce meaning or generate noise.
There is minimal semantic drift between the homepage signal and the sub-page substance; the hero section promises information on how the drug works, and the sub-pages provide the specific dual-action mechanism. A minor technical disconnect exists where the H1 tag on every page is ‘Interest-Based Ads’, which is a legal/privacy label rather than a content-aligned heading. Aside from this technical error, the messaging remains strictly consistent between the English and Spanish versions.
Transition from a collection of strings to a machine verifiable identity. Generate your Clinical SEO Strategy to establish a robust Knowledge Graph Topology and eliminate semantic black holes.
The site avoids common trust theatre traps like unverified reviews (review_count: 0) or fake award badges. However, it lacks a direct proof path to external validation; while clinical trials are mentioned in meta descriptions, the clean text fails to provide outbound links to peer-reviewed studies or ClinicalTrials.gov registrations. The presence of the ‘Maximum Fair Price’ effective January 1, 2026, adds a layer of real-world regulatory substance that is rarely seen on fluff-heavy sites.
The ratio of evidence to assertions is moderate. Verifiable evidence includes the specific chemical ingredients and the precise symptom thresholds for fluid retention. Unsubstantiated claims include the ‘world of possibilities’ phrasing and general efficacy statements that lack direct citation in the crawled passages. The presence of detailed safety warnings and contraindications serves as ‘reverse-proof’ of the drug’s potency and regulated status.
To see how the system reconstructs a medical entity graph at scale, review the full Cleveland Clinic Structured Data audit. View the Cleveland Clinic Structured Data Audit for a live example of identity level decomposition and cross page entity mapping.
While the drug’s mechanism is unique, the value proposition follows standard pharmaceutical cliches such as ‘Treating your heart failure may lead to a world of possibilities’. The structure is a textbook template for drug marketing, featuring the mandatory ISI and Indication blocks. It avoids the highest penalties because the product (a patented molecule) cannot be easily substituted by a competitor’s copy-paste, unlike service-based industries.
There is a significant technical authority gap; the site claims to be a primary source for medical information but fails to implement any Schema.org structured data (schema_json: null). Furthermore, the expert authority is generic (‘talk to your doctor’) with no named clinical leads or researchers from Novartis identified within the content. The technical error of having ‘Interest-Based Ads’ as the primary H1 across all pages suggests a lack of professional digital oversight.
The site makes a bold performance claim: ‘reduce the risk of death and hospitalization’. While this is the drug’s approved indication, the provided text does not cite the specific percentage reduction or the name of the pivotal clinical trial (e.g., PARADIGM-HF) that proved it. The marketing tone remains relatively sober, but the lack of immediate, visible data points to back up the ‘reduce death’ claim in the clean text creates a small evidentiary gap.
Medical Devices, Pharma & Biotech BS: ENTRESTO (entresto.com)
The website perfectly aligns with the Pharmaceutical industry, characterized by mandatory Important Safety Information (ISI) blocks and specific therapeutic indications. The content focuses on a specific mechanism of action (sacubitril/valsartan) and follows the regulatory communication patterns typical of FDA-regulated drug products.
Before embeddings, before entities, before retrieval — the crawler must reach the text. Open the Crawlability & Indexation Guide to learn how access failures erase meaning long before interpretation begins.
“The score of 33 is primarily driven by the Identity and Authority pillar (12/15) due to the total absence of Schema and the broken H1 hierarchy. Information Density also contributed points (9/30) due to redundant messaging across the multi-page structure. The site's compliance with pharma regulations keeps the Trust and Commodity scores very low, preventing it from reaching a 'Moderate BS' rating.”
Analysis Disclosure & Source Attribution
Snapshot Date: May 30, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at ENTRESTO to view the most current version of their content and see directly what the company offers.